MARTINSRIED, Germany & MUNICH--(BUSINESS WIRE)--The drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) today announced that it will present new pre-clinical data on 4SC-101, a small molecule for the treatment of inflammatory bowel disease (IBD), at the Digestive Disease Week (DDW) conference in Chicago, USA, from May 30 to June 4, 2009. Jointly with its collaborator Leo R. Fitzpatrick from the Department of Pharmacology, Penn State College of Medicine, USA, 4SC will present data on the efficacy of 4SC-101 in an established pre-clinical model for IBD, which demonstrated that 4SC-101 significantly improved various disease parameters and inhibited the colonic expression of pro-inflammatory cytokines IL-17 and Interferon-gamma (IFN-gamma).
